{"protocolSection":{"identificationModule":{"nctId":"NCT02450539","orgStudyIdInfo":{"id":"15806"},"secondaryIdInfos":[{"id":"I3Y-MC-JPBX","type":"OTHER","domain":"Eli Lilly and Company"},{"id":"2014-004832-20","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer","officialTitle":"A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy"},"statusModule":{"statusVerifiedDate":"2021-07-15","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":true,"nctId":"NCT03763604","statusForNctId":"APPROVED_FOR_MARKETING"},"startDateStruct":{"date":"2015-08-06","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-03-31","type":"ACTUAL"},"completionDateStruct":{"date":"2020-07-29","type":"ACTUAL"},"studyFirstSubmitDate":"2015-05-19","studyFirstSubmitQcDate":"2015-05-19","studyFirstPostDateStruct":{"date":"2015-05-21","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-03-30","resultsFirstSubmitQcDate":"2018-05-25","resultsFirstPostDateStruct":{"date":"2018-06-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-07-26","lastUpdatePostDateStruct":{"date":"2021-08-13","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The main purpose of this study is to evaluate the effectiveness of the study drug known as abemaciclib versus docetaxel in participants with stage IV squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer Stage IV"],"keywords":["patient reported outcomes (PRO)","patient focused outcomes (PFO)","biomarkers","CDK 4 and 6"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":159,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Abemaciclib","type":"EXPERIMENTAL","description":"200 milligram (mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","interventionNames":["Drug: Abemaciclib"]},{"label":"Docetaxel","type":"ACTIVE_COMPARATOR","description":"75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","interventionNames":["Drug: Docetaxel"]}],"interventions":[{"type":"DRUG","name":"Abemaciclib","description":"Administered orally","armGroupLabels":["Abemaciclib"],"otherNames":["LY2835219"]},{"type":"DRUG","name":"Docetaxel","description":"Administered IV","armGroupLabels":["Docetaxel"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival (PFS)","description":"PFS was defined as time from the date of randomization to the date of investigator-determined disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause. Progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameters (LD) of target lesions, with reference the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant was not known to have died or have objective progression, PFS time will be censored at the day of their last radiographic tumor assessment (if available) or date of randomization if no post baseline radiographic assessment is available.","timeFrame":"Baseline to Objective Progression or Death from Any Cause ( Up To 6 Months)"}],"secondaryOutcomes":[{"measure":"Pharmacokinetics (PK): Clearance of Abemaciclib","description":"Pharmacokinetics (PK): Clearance of Abemaciclib","timeFrame":"Cycle (C) 1 Day (D) 1: Pre-dose; C1D8: 4 and 7 hr Post-dose; C2D1: Pre-dose and 3 hr Post-dose; C3 and C4 D1:Pre-dose"},{"measure":"PK: Volume of Distribution of Abemaciclib","description":"PK: Volume of Distribution of Abemaciclib","timeFrame":"Cycle (C) 1 Day (D) 1: Pre-dose; C1D8: 4 and 7 hr Post-dose; C2D1: Pre-dose and 3 hr Post-dose; C3 and C4 D1:Pre-dose"},{"measure":"Overall Survival (OS)","description":"OS was defined as the time from randomization to the date of death due to any cause. For each participant who is not known to have died as the data inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.","timeFrame":"Baseline to Date of Death from Any Cause (Up To 28 Months)"},{"measure":"Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])","description":"Overall response was defined as the percentage of randomized participants achieving a best overall response (BoR) of complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. Participants with unevaluable or unknown response status are considered nonresponders. Complete response (CR) is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions.","timeFrame":"Baseline to Objective Progression (Up To 6 Months)"},{"measure":"Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR): Disease Control Rate (DCR)","description":"DCR is the percentage of randomized participants who achieved a complete response, partial response or stable disease using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. Complete response (CR) is defined as the disappearance of all target and non-target lesions, and no appearance of new lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions. Stable disease was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions.","timeFrame":"Baseline through Measured Progressive Disease or Death Due to Any Cause (Up To 6 Months)"},{"measure":"Time to Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status of >/=2","description":"Worsening of ECOG performance status is the duration from randomization to ECOG PFS of \\>/=2. Participants without an ECOG PFS \\>/=2 are censored at last adequate post baseline ECOG Performance Status or randomization date (whichever is last).\n\nThe ECOG Performance Status:0 - Fully active, able to carry on all pre-disease performance without restriction,1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2 - Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours,3 - Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4 - Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5 - Dead","timeFrame":"Randomization to ECOG PFS of >/=2 (Up To 11.5 Months)"},{"measure":"Change From Baseline in MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) Scores","description":"MDASI-LC included 33 items:6 interference and 27 symptom(3 lung-cancer (LC),8 brain tumor (BT),and 3 study-specific(headache,diarrhea, and rash).Analyzed endpoints were 9 constructs:3 single-items (headache,diarrhea,and rash) and 6 composites(interference+core,LC,core+LC,BT, and core+LC worst 5 baseline).Data for all 9 constructs were collected by an 11-point numeric rating scale anchored at 0(not present or does not interfere) and 10(as bad as you can imagine or interfered completely).The measurement range was 10 (maximum score-minimum score). Between-group difference in regression-predicted change from baseline were estimated for each specified construct. MMRM models included independent variables treatment,visit, treatment\\*visit,and baseline score. Group-level negative change from baseline indicated group improvement.","timeFrame":"Baseline through End of Study (Up To 6 Months)"},{"measure":"Change From Baseline in EuroQol 5-Dimensional 5-Level (EQ-5D-5L) Questionnaire EQ VAS Overall Self-rated Health Score","description":"The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Overall self-rated health was measured with a vertical 20 cm visual analog scale (VAS) anchored at 0 (worst health) and ranged through 100 (best health). Between-group differences in regression-predicted change from baseline score were estimated for VAS scores. MMRM models included independent variables treatment, visit, treatment\\*visit, and baseline score. Group-level negative change from baseline indicated group improvement.","timeFrame":"Baseline to Measured Progressive Disease (Up To 6 Months)"},{"measure":"Change From Baseline in EuroQol 5-Dimensional 5-Level (EQ-5D-5L) Questionnaire Index Value","description":"There are 5 response levels on a good-to-bad continuum of 1-5 corresponding to none, slight, moderate, severe, and extreme/unable to.The EuroQol-developed crosswalk method was used to convert the EQ-5D-5L,using UK weights,health dimensions(mobility,self-care,usual activities,pain/discomfort, and anxiety/depression) into a single index value;the dimensions are not separately scored.The index is marked missing when ≥1 dimensions are missing.The index scores for the response patterns were anchored on full health to dead with negative values assigned to response patterns/health states considered worse than death.The best pattern is assigned the index value of 1.0; the worst pattern is assigned an index value of -0.594. Between-group differences in regression-predicted change from baseline score were estimated for the index .MMRM models included independent variables treatment, visit, treatment\\*visit, and baseline score.Group-level negative change from baseline indicated group improvement.","timeFrame":"Baseline to Measured Progressive Disease (Up To 6 Months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed diagnosis of stage IV NSCLC.\n* Have progressed during or after platinum-based chemotherapy for advanced disease.\n* Have not received prior treatment with docetaxel.\n* Have availability of adequate formalin-fixed paraffin-embedded (FFPE) tumor derived material.\n* Have adequate organ function including hematology, renal, and liver.\n* Have good performance score (0-1).\n* Have measurable disease per RECIST 1.1.\n* Agree to use a reliable medically approved method of birth control.\n\nExclusion Criteria:\n\n* Have received prior treatment with any cyclin dependent kinase (CDK) 4 and 6 inhibitor or participated in a clinical trial with a CDK 4 and 6 inhibitor and the treatment administered is not known.\n* Are currently receiving treatment in a clinical trial involving an investigational product or non-approved use of a drug or device.\n* Have the presence of unstable central nervous system (CNS) metastasis.\n* Have had major surgery (excluding biopsy) \\< 28 days of the initial dose of study drug.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Highlands Oncology Group","city":"Fayetteville","state":"Arkansas","zip":"72703","country":"United States","geoPoint":{"lat":36.06258,"lon":-94.15743}},{"facility":"Cancer Center of Kansas, P.A.","city":"Wichita","state":"Kansas","zip":"67214","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"Washington University School of Medicine","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Montefiore Medical Center","city":"The Bronx","state":"New York","zip":"10461","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"Vista Oncology Inc. PS","city":"Olympia","state":"Washington","zip":"98502","country":"United States","geoPoint":{"lat":47.04491,"lon":-122.90169}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Camperdown","zip":"2050","country":"Australia","geoPoint":{"lat":-33.88965,"lon":151.17642}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Randwick","zip":"2013","country":"Australia","geoPoint":{"lat":-33.91439,"lon":151.24895}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"South Brisbane","zip":"4101","country":"Australia","geoPoint":{"lat":-27.48034,"lon":153.02049}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wollongong","zip":"2500","country":"Australia","geoPoint":{"lat":-34.424,"lon":150.89345}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Woolloongabba","zip":"4102","country":"Australia","geoPoint":{"lat":-27.48855,"lon":153.03655}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Paris","zip":"75970","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Strasbourg","zip":"67091","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Suresnes","zip":"92150","country":"France","geoPoint":{"lat":48.87143,"lon":2.22929}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Berlin","zip":"14165","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cologne","zip":"51109","country":"Germany","geoPoint":{"lat":50.93333,"lon":6.95}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Gera","zip":"07548","country":"Germany","geoPoint":{"lat":50.88029,"lon":12.08187}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Halle","zip":"06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Heidelberg","zip":"69126","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Budapest","zip":"1121","country":"Hungary","geoPoint":{"lat":47.49835,"lon":19.04045}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Győr","zip":"9023","country":"Hungary","geoPoint":{"lat":47.68333,"lon":17.63512}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bari","zip":"70124","country":"Italy","geoPoint":{"lat":41.12066,"lon":16.86982}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Florence","zip":"50134","country":"Italy","geoPoint":{"lat":43.77925,"lon":11.24626}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Monza","zip":"20900","country":"Italy","geoPoint":{"lat":45.58005,"lon":9.27246}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Torino","zip":"10043","country":"Italy","geoPoint":{"lat":44.88856,"lon":11.99138}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Krakow","zip":"31-202","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Lodz","zip":"90-242","country":"Poland","geoPoint":{"lat":51.77058,"lon":19.47395}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Olsztyn","zip":"10-357","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Poznan","zip":"60-569","country":"Poland","geoPoint":{"lat":52.40692,"lon":16.92993}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Warsaw","zip":"04-125","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Baia Mare","zip":"430031","country":"Romania","geoPoint":{"lat":47.65729,"lon":23.56808}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cluj-Napoca","zip":"400015","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cluj-Napoca","zip":"400058","country":"Romania","geoPoint":{"lat":46.76667,"lon":23.6}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Craiova","zip":"200347","country":"Romania","geoPoint":{"lat":44.31667,"lon":23.8}},{"facility":"St-Petersburg scientifical practical center of specialized kinds of medical care (oncological)","city":"Saint Petersburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Volgograd regional clinical oncology dispensary","city":"Volzhsky","zip":"404130","country":"Russia","geoPoint":{"lat":48.78583,"lon":44.77973}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Cheongju-si","zip":"28644","country":"South Korea","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Seoul","zip":"06351","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician","city":"Seoul","zip":"06591","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ulsan","zip":"44033","country":"South Korea","geoPoint":{"lat":35.53722,"lon":129.31667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Barcelona","zip":"08025","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Madrid","zip":"28223","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Pamplona","zip":"31008","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Seville","zip":"41071","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Taichung","zip":"40447","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Tainan","zip":"70403","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Taipei","zip":"10048","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Dnipropetrovsk","zip":"49102","country":"Ukraine","geoPoint":{"lat":48.46664,"lon":35.04066}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kharkiv","zip":"61070","country":"Ukraine","geoPoint":{"lat":49.98177,"lon":36.25475}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Kryvyi Rih","zip":"50048","country":"Ukraine","geoPoint":{"lat":47.90572,"lon":33.39404}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Vinnitsa","zip":"21029","country":"Ukraine","geoPoint":{"lat":49.84639,"lon":37.71861}}]},"referencesModule":{"seeAlsoLinks":[{"label":"A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer","url":"https://trials.lillytrialguide.com/en-US/trial/3fFmhLPCZ2EGMW8w6gCq0Y?conditionId=WWF5j0kxgqI0QYaYMo04G"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Study completers are participants who died due to any cause, were on follow-up at study completion or completed continued access period.","groups":[{"id":"FG000","title":"Abemaciclib","description":"200 milligram(mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"FG001","title":"Docetaxel","description":"75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"106"},{"groupId":"FG001","numSubjects":"53"}]},{"type":"Received at Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"106"},{"groupId":"FG001","numSubjects":"52"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"90"},{"groupId":"FG001","numSubjects":"46"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"16"},{"groupId":"FG001","numSubjects":"7"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants.","groups":[{"id":"BG000","title":"Abemaciclib","description":"200 milligram(mg) Abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"BG001","title":"Docetaxel","description":"75 milligram per meter squared (mg/m²) Docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"106"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"159"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63.1","spread":"7.8"},{"groupId":"BG001","value":"64.5","spread":"7.1"},{"groupId":"BG002","value":"63.5","spread":"7.6"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"16"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"25"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"90"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"134"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"132"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"19"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"13"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"96"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"146"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Romania","categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"22"}]}]},{"title":"Hungary","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"13"}]}]},{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]}]},{"title":"Ukraine","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"26"}]}]},{"title":"Russia","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"13"}]}]},{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"14"}]}]},{"title":"South Korea","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"9"}]}]},{"title":"Taiwan","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}]},{"title":"Poland","categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"24"}]}]},{"title":"Italy","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"8"}]}]},{"title":"Australia","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"}]}]},{"title":"France","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]},{"title":"Germany","categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"13"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)","description":"Participants were stratified at randomization according to the following: Eastern Cooperative Oncology Group (ECOG) PS (0 vs. 1); number of prior therapies (received only platinum-based therapy vs. platinum-based therapy plus immune checkpoint inhibitor) and time since initiation of first line therapy (\\<=9 months vs \\>9 months). The ECOG Performance Status:0 - Fully active, able to carry on all pre-disease performance without restriction,1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"0","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"29"}]},{"title":"1","measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"130"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS)","description":"PFS was defined as time from the date of randomization to the date of investigator-determined disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause. Progressive disease (PD) was defined as at least a 20% increase in the sum of the longest diameters (LD) of target lesions, with reference the smallest sum on study and an absolute increase of at least 5mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant was not known to have died or have objective progression, PFS time will be censored at the day of their last radiographic tumor assessment (if available) or date of randomization if no post baseline radiographic assessment is available.","populationDescription":"All participants according to the treatment group to which they were randomized. Participants censored: Abemaciclib=19 and Docetaxel= 15.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to Objective Progression or Death from Any Cause ( Up To 6 Months)","groups":[{"id":"OG000","title":"Abemaciclib","description":"200 milligram(mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Docetaxel","description":"75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"53"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.53","lowerLimit":"1.68","upperLimit":"2.89"},{"groupId":"OG001","value":"4.21","lowerLimit":"2.79","upperLimit":"5.65"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Stratified by baseline ECOG performance status (0 vs 1), number of Prior Therapies (received only platinum-based therapy vs Received platinum-based Therapy plus Immune Checkpoint Inhibitor), and time since initiation of first line therapy (\\<=9 months vs \\>9 months).","nonInferiorityType":"SUPERIORITY","pValue":"0.0068","statisticalMethod":"Stratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"1.765","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.165","ciUpperLimit":"2.672","estimateComment":"Stratified Cox proportional hazard model"}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Clearance of Abemaciclib","description":"Pharmacokinetics (PK): Clearance of Abemaciclib","populationDescription":"All participants who received abemaciclib and had evaluable PK data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Liters/hour (L/h)","timeFrame":"Cycle (C) 1 Day (D) 1: Pre-dose; C1D8: 4 and 7 hr Post-dose; C2D1: Pre-dose and 3 hr Post-dose; C3 and C4 D1:Pre-dose","groups":[{"id":"OG000","title":"Abemaciclib","description":"200 milligram(mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":"36"}]}]}]},{"type":"SECONDARY","title":"PK: Volume of Distribution of Abemaciclib","description":"PK: Volume of Distribution of Abemaciclib","populationDescription":"All participants who received Abemaciclib and had evaluable PK data.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Liters (L)","timeFrame":"Cycle (C) 1 Day (D) 1: Pre-dose; C1D8: 4 and 7 hr Post-dose; C2D1: Pre-dose and 3 hr Post-dose; C3 and C4 D1:Pre-dose","groups":[{"id":"OG000","title":"Abemaciclib","description":"200 milligram(mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"102"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"769","spread":"51"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS was defined as the time from randomization to the date of death due to any cause. For each participant who is not known to have died as the data inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.","populationDescription":"All participants according to the treatment group to which they were randomized. Participants censored: Abemaciclib=35 and Docetaxel= 17.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline to Date of Death from Any Cause (Up To 28 Months)","groups":[{"id":"OG000","title":"Abemaciclib","description":"200 milligram(mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Docetaxel","description":"75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"53"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","lowerLimit":"5.00","upperLimit":"8.78"},{"groupId":"OG001","value":"12.39","lowerLimit":"7.13","upperLimit":"15.98"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Stratified by baseline ECOG performance status (0 vs 1), number of Prior Therapies (received only platinum-based therapy vs Received platinum-based Therapy plus Immune Checkpoint Inhibitor), and time since initiation of first line therapy (\\<=9 months vs \\>9 months).\\]","nonInferiorityType":"SUPERIORITY","pValue":"0.1746","statisticalMethod":"Stratified log-rank test","paramType":"Hazard Ratio (HR)","paramValue":"1.333","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.879","ciUpperLimit":"2.022","estimateComment":"Stratified Cox proportional hazard model"}]},{"type":"SECONDARY","title":"Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])","description":"Overall response was defined as the percentage of randomized participants achieving a best overall response (BoR) of complete response (CR) or partial response (PR) using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. Participants with unevaluable or unknown response status are considered nonresponders. Complete response (CR) is defined as the disappearance of all target and non-target lesions and no appearance of new lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions.","populationDescription":"All randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage participants","timeFrame":"Baseline to Objective Progression (Up To 6 Months)","groups":[{"id":"OG000","title":"Abemaciclib","description":"200 milligram(mg) Abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Docetaxel","description":"75 milligram per meter squared (mg/m²) Docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"53"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.8"},{"groupId":"OG001","value":"20.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Rate Difference","paramValue":"-17.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-29.3","ciUpperLimit":"-6.6","estimateComment":"Confidence intervals are based on the normal approximation to the binomial."}]},{"type":"SECONDARY","title":"Percentage of Participants Who Exhibit Stable Disease (SD) or Confirmed Response (CR) or Partial Response (PR): Disease Control Rate (DCR)","description":"DCR is the percentage of randomized participants who achieved a complete response, partial response or stable disease using Response Evaluation Criteria In Solid Tumors (RECIST v1.1) criteria. Complete response (CR) is defined as the disappearance of all target and non-target lesions, and no appearance of new lesions. Partial response (PR) is defined as at least a 30% decrease in the sum of longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions and no appearance of new lesions. Stable disease was neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD for target lesions, no progression of non-target lesions, and no appearance of new lesions.","populationDescription":"All randomized participants.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"percentage participants","timeFrame":"Baseline through Measured Progressive Disease or Death Due to Any Cause (Up To 6 Months)","groups":[{"id":"OG000","title":"Abemaciclib","description":"200 milligram(mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Docetaxel","description":"75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"53"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.9"},{"groupId":"OG001","value":"64.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Rate Difference","paramValue":"-13.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-29.2","ciUpperLimit":"2.8","estimateComment":"Confidence intervals are based on the normal approximation to the binomial."}]},{"type":"SECONDARY","title":"Time to Worsening of Eastern Cooperative Oncology Group (ECOG) Performance Status of >/=2","description":"Worsening of ECOG performance status is the duration from randomization to ECOG PFS of \\>/=2. Participants without an ECOG PFS \\>/=2 are censored at last adequate post baseline ECOG Performance Status or randomization date (whichever is last).\n\nThe ECOG Performance Status:0 - Fully active, able to carry on all pre-disease performance without restriction,1 - Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, 2 - Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours,3 - Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4 - Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5 - Dead","populationDescription":"All randomized participants. Participants censored: Abemaciclib =93 and Docetaxel= 43.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to ECOG PFS of >/=2 (Up To 11.5 Months)","groups":[{"id":"OG000","title":"Abemaciclib","description":"200 milligram(mg) Abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Docetaxel","description":"75 milligram per meter squared (mg/m²) Docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"53"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"6.58","upperLimit":"NA","comment":"Due to insufficient data to support the analysis and the results."},{"groupId":"OG001","value":"10.52","lowerLimit":"4.64","upperLimit":"NA","comment":"Due to insufficient data to support the analysis and the results."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Stratification factors are baseline ECOG performance status (0 vs 1), Number of Prior Therapies (received only platinum-based therapy vs Received platinum-based Therapy plus Immune Checkpoint Inhibitor), and time since initiation of first line therapy (\\<=9 months vs \\>9 months).","nonInferiorityType":"SUPERIORITY","pValue":"0.7039","statisticalMethod":"Stratified Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.184","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.502","ciUpperLimit":"2.792","estimateComment":"Stratified Cox regression model."}]},{"type":"SECONDARY","title":"Change From Baseline in MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) Scores","description":"MDASI-LC included 33 items:6 interference and 27 symptom(3 lung-cancer (LC),8 brain tumor (BT),and 3 study-specific(headache,diarrhea, and rash).Analyzed endpoints were 9 constructs:3 single-items (headache,diarrhea,and rash) and 6 composites(interference+core,LC,core+LC,BT, and core+LC worst 5 baseline).Data for all 9 constructs were collected by an 11-point numeric rating scale anchored at 0(not present or does not interfere) and 10(as bad as you can imagine or interfered completely).The measurement range was 10 (maximum score-minimum score). Between-group difference in regression-predicted change from baseline were estimated for each specified construct. MMRM models included independent variables treatment,visit, treatment\\*visit,and baseline score. Group-level negative change from baseline indicated group improvement.","populationDescription":"All randomized participants for cycles which at least 25% of participants in each arm have a score.MDASI-LC population included all randomized participants who completed at least 1 baseline assessment followed by at least 1 MDASI-LC assessment after Cycle 1 (for example, a completed MDASI-LC questionnaire at Cycle 2 Day 1 or later)","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline through End of Study (Up To 6 Months)","groups":[{"id":"OG000","title":"Abemaciclib","description":"200 milligram(mg) Abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Docetaxel","description":"75 milligram per meter squared (mg/m²) Docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"43"}]}],"classes":[{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"0.14"},{"groupId":"OG001","value":"0.01","spread":"0.18"}]}]},{"title":"Diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"0.18"},{"groupId":"OG001","value":"0.15","spread":"0.23"}]}]},{"title":"Mean core symptom severity","categories":[{"measurements":[{"groupId":"OG000","value":"0.53","spread":"0.14"},{"groupId":"OG001","value":"0.00","spread":"0.18"}]}]},{"title":"Mean interference","categories":[{"measurements":[{"groupId":"OG000","value":"0.50","spread":"0.20"},{"groupId":"OG001","value":"0.18","spread":"0.27"}]}]},{"title":"Mean lung cancer symptom severity","categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.12"},{"groupId":"OG001","value":"-0.19","spread":"0.15"}]}]},{"title":"Mean core plus lung cancer symptom severity","categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"0.13"},{"groupId":"OG001","value":"-0.04","spread":"0.17"}]}]},{"title":"Mean brain tumor symptom severity","categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"0.11"},{"groupId":"OG001","value":"0.13","spread":"0.15"}]}]},{"title":"Mean core plus lung worst 5 symptoms severity","categories":[{"measurements":[{"groupId":"OG000","value":"-0.25","spread":"0.17"},{"groupId":"OG001","value":"-0.94","spread":"0.22"}]}]},{"title":"Rash","categories":[{"measurements":[{"groupId":"OG000","value":"0.28","spread":"0.14"},{"groupId":"OG001","value":"0.18","spread":"0.17"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Headache","nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.18","ciNumSides":"TWO_SIDED","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.23"},{"groupIds":["OG000","OG001"],"groupDescription":"Diarrhea","nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.86","ciNumSides":"TWO_SIDED","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.29"},{"groupIds":["OG000","OG001"],"groupDescription":"Mean core symptom severity","nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.53","ciNumSides":"TWO_SIDED","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.22"},{"groupIds":["OG000","OG001"],"groupDescription":"Mean interference","nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.32","ciNumSides":"TWO_SIDED","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.34"},{"groupIds":["OG000","OG001"],"groupDescription":"Mean lung cancer symptom severity","nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.39","ciNumSides":"TWO_SIDED","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.19"},{"groupIds":["OG000","OG001"],"groupDescription":"Mean core plus lung cancer symptom severity","nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.52","ciNumSides":"TWO_SIDED","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.21"},{"groupIds":["OG000","OG001"],"groupDescription":"Mean brain tumor symptom severity","nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.06","ciNumSides":"TWO_SIDED","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.19"},{"groupIds":["OG000","OG001"],"groupDescription":"Mean core plus lung worst 5 symptoms severity","nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.69","ciNumSides":"TWO_SIDED","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.28"},{"groupIds":["OG000","OG001"],"groupDescription":"Rash","nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"0.09","ciNumSides":"TWO_SIDED","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.22"}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol 5-Dimensional 5-Level (EQ-5D-5L) Questionnaire EQ VAS Overall Self-rated Health Score","description":"The EQ-5D-5L is a standardized instrument for use as a measure of self-reported health status. Overall self-rated health was measured with a vertical 20 cm visual analog scale (VAS) anchored at 0 (worst health) and ranged through 100 (best health). Between-group differences in regression-predicted change from baseline score were estimated for VAS scores. MMRM models included independent variables treatment, visit, treatment\\*visit, and baseline score. Group-level negative change from baseline indicated group improvement.","populationDescription":"All randomized participants for cycles which at least 25% of participants in each arm have a score.The EQ-5D-5L population included all randomized participants who completed at least 1 baseline assessment followed by at least 1 EQ-5D-5L assessment after Cycle 1 (for example, a completed EQ-5D-5L questionnaire at Cycle 2 Day 1 or later).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline to Measured Progressive Disease (Up To 6 Months)","groups":[{"id":"OG000","title":"Abemaciclib","description":"200 milligram(mg) Abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Docetaxel","description":"75 milligram per meter squared (mg/m²) Docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"42"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.49","spread":"1.28"},{"groupId":"OG001","value":"-2.36","spread":"1.63"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"EQ VAS Overall Self-rated Health Score","nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"-3.13","ciNumSides":"TWO_SIDED","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"2.07"}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQol 5-Dimensional 5-Level (EQ-5D-5L) Questionnaire Index Value","description":"There are 5 response levels on a good-to-bad continuum of 1-5 corresponding to none, slight, moderate, severe, and extreme/unable to.The EuroQol-developed crosswalk method was used to convert the EQ-5D-5L,using UK weights,health dimensions(mobility,self-care,usual activities,pain/discomfort, and anxiety/depression) into a single index value;the dimensions are not separately scored.The index is marked missing when ≥1 dimensions are missing.The index scores for the response patterns were anchored on full health to dead with negative values assigned to response patterns/health states considered worse than death.The best pattern is assigned the index value of 1.0; the worst pattern is assigned an index value of -0.594. Between-group differences in regression-predicted change from baseline score were estimated for the index .MMRM models included independent variables treatment, visit, treatment\\*visit, and baseline score.Group-level negative change from baseline indicated group improvement.","populationDescription":"All randomized participants for cycles which at least 25% of participants in each arm have a score.The EQ-5D-5L population included all randomized participants who completed at least 1 baseline assessment followed by at least 1 EQ-5D-5L assessment after Cycle 1 (for example, a completed EQ-5D-5L questionnaire at Cycle 2 Day 1 or later).","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"units on a scale","timeFrame":"Baseline to Measured Progressive Disease (Up To 6 Months)","groups":[{"id":"OG000","title":"Abemaciclib","description":"200 milligram(mg) Abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."},{"id":"OG001","title":"Docetaxel","description":"75 milligram per meter squared (mg/m²) Docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"42"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.05","spread":"0.02"},{"groupId":"OG001","value":"-0.01","spread":"0.02"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"EQ-5D-5L Index Value","nonInferiorityType":"SUPERIORITY","paramType":"Median Difference (Final Values)","paramValue":"-0.04","ciNumSides":"TWO_SIDED","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.03"}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline Up To 5 Years","description":"All randomized participants who received at least one dose of study drug.","eventGroups":[{"id":"EG000","title":"Abemaciclib","description":"200 milligram(mg) abemaciclib given orally every 12 hours (Q12H) on days 1 to 21 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","deathsNumAffected":71,"deathsNumAtRisk":106,"seriousNumAffected":29,"seriousNumAtRisk":106,"otherNumAffected":94,"otherNumAtRisk":106},{"id":"EG001","title":"Docetaxel","description":"75 milligram per meter squared (mg/m²) docetaxel given intravenously (IV) on day 1 of each 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.","deathsNumAffected":35,"deathsNumAtRisk":52,"seriousNumAffected":17,"seriousNumAtRisk":52,"otherNumAffected":43,"otherNumAtRisk":52}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":52}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Cardiovascular insufficiency","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Oesophageal fistula","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":106},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":52}]},{"term":"Myelitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Pleural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Salmonella bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"International normalised ratio increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Laryngeal haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Pulmonary haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":47,"numAffected":41,"numAtRisk":106},{"groupId":"EG001","numEvents":18,"numAffected":12,"numAtRisk":52}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":106},{"groupId":"EG001","numEvents":48,"numAffected":14,"numAtRisk":52}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":18,"numAtRisk":106},{"groupId":"EG001","numEvents":76,"numAffected":26,"numAtRisk":52}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":27,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":67,"numAffected":41,"numAtRisk":106},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":52}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":33,"numAtRisk":106},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":52}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":34,"numAffected":30,"numAtRisk":106},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":52}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":106},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":52}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":13,"numAtRisk":106},{"groupId":"EG001","numEvents":6,"numAffected":1,"numAtRisk":52}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":106},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":52}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":17,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":52}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":52}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":10,"numAtRisk":106},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":52}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":52}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":52}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":19,"numAtRisk":106},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":52}]},{"term":"Laryngeal haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":52}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":52}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":52}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 23.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":52}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","email":"ClinicalTrials.gov@lilly.com","phone":"800-545-5979"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2020-02-12","uploadDate":"2021-04-16T15:51","filename":"Prot_002.pdf","size":5160207},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2015-06-09","uploadDate":"2018-03-29T15:20","filename":"SAP_001.pdf","size":440176}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000590451","term":"abemaciclib"},{"id":"D000077143","term":"Docetaxel"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"}]}},"hasResults":true}